Interview with Jean-Pierre Delwart, Chief Executive Officer, Eurogentec Belgium
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Address: p/a Multiburo
Kievitplein 20C/12
B-2018 ANTWERPEN – Belgium
Tel: +32 (0)3 897 19 00
Galderma is a global pharmaceutical company specializing in research, development and marketing of therapeutic, corrective and aesthetic solutions for dermatology patients in the prevention, diagnosis and treatment of dermatological disorders. More and more Galderma presents itself as an innovator in dermatology.
Galderma provides innovative medical solutions that meet the needs of dermatology patients and physicians with a particular focus on acne, rosacea, psoriasis and other steroid-responsive dermatoses (SRD), onychomycosis (fungal nail infections), pigmentary disorders, skin cancer aned medical solutions for skin senescence. The skin conditions we treat can have strong psychological and social implications in the everyday lives of our patients. By treating these conditions, we help people preserve, restore and maintain a healthy skin and improve their quality of life.
Mr Delwart, you have been acting CEO of EuroGenTec for an impressive 19 years. During your tenure, what would you say has been the single most important change in the…
Can you illustrate to our readers the company’s main milestones and key achievements since you took the reins four years ago? In the last years we have experienced a period…
Let us begin by getting an overview of APB’s functions & objectives and your role within the association as General Manager? The Belgian Association of Pharmacists is a federation of…
Mr Bravo, in relation to your previous career in big pharma companies, you have recently made a shift into much smaller entities including Cellerix and TiGenix. What motivated you to…
Looking into your background, we see that you have developed your career in the local industry’s top 3 players: Pfizer, AstraZeneca and Novartis until assuming your position as General Manager…
Oystershell was founded in 1979, however in 2002 the company was taken over by you and your team in a MBO. Can you tell our readers more about what motivated…
Can you tell our readers about B&C Groups main mission and also highlight some of its most notable achievements and milestones since its founding in 1999? Earlier in my career,…
Looking at your background, we see that you have been with IMS for over 12 years. What defines your loyalty to the company? What appeals most to you about IMS?…
Can you begin by giving us a brief overview of Amgen in Belgium and tell our readers more about the company’s history here? Compared to other, well-established multinationals Amgen is…
Mr. De Cuyper, can you start with a brief introduction to the federal agency for medicines and health products (famhp) and its role within the Belgium’s complex regulatory environment? We…
Looking into your background, we see that you’ve spent 8 years at pharma.be, where you were advocating the traditional drug producers. What encouraged you to head FeBelGen since 2006, representing…
In your 8 years of experience within the group, how would you classify the competitive advantages derived for the company’s unique familial ownership structure? Due to its history and strong…
See our Cookie Privacy Policy Here